Alloy Therapeutics

Alloy Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceswww.alloytx.com

Last Round

Series E

Apr 15, 2026

Est. Valuation

$1B

Total Funding Raised

$134.5M

Company Overview

Alloy Therapeutics is a biotechnology company that offers a drug discovery platform aimed at enhancing and streamlining antibody discovery projects through its innovative humanized transgenic antibody technology.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Biotech Equipment, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Subscription SaaS

AI Layer

Application

Keywords

antibody discovery platformtransgenic micehuman antibody discoverydrug discovery servicescontract research organizationCROtechnology licensingantibody engineeringVHH discoverysingle-domain antibodiesbiotech picks and shovelsmonoclonal antibodiescomputational antibody designantibody-drug conjugatesbiotechnology ecosystem

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alloy Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Alloy Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series EApr 15, 2026
Series DOct 3, 2022
Series CApr 2, 2021

Key People

Founding team and executive leadership

Dongxing Zha

CTO, TCR Discovery And Engineering At Alloy Therapeutics Founder And CEO At Keyway TCR Discovery

Founding Team

Kelsey Cardenas

Director, Office Of The CEO

Executive Team

Logan Snyder

Board Member, Office Of The CEO

Executive Team

Jeff Swenson

Acting Chief Financial Officer

Executive Team

Alloy Therapeutics Investors

Notable investors and investment history

InvestorRounds
Echo Investment CapitalSeries E
Thiel CapitalSeries E, Series D
GaingelsSeries C, Series E
Founders FundSeries C, Series E, Series D
Presight CapitalSeries E, Series D, Series C
JIC Venture Growth InvestmentsSeries E
Mubadala CapitalSeries E

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    100% of revenue reinvested into innovation and access.

  • Apr 15, 2026

    $40M round closed at $1B valuation.

Alloy Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alloy Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alloy Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range133
Year Founded2017
Last FundingApr 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.